Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19 by Focosi, Daniele et al.
4/8/2021 Early Release - Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19 - Volume 27, Number 10—October 2021 - Emerging Infectious Diseases journal - CDC
https://wwwnc.cdc.gov/eid/article/27/10/21-1538_article 1/4
ISSN: 1080-6059
Disclaimer: Early release articles are not considered as  nal versions. Any changes will be re ected in the online version in the month the article is o cially released.
Volume 27, Number 10—October 2021
Research Letter
Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after
Treatment for COVID-19
Daniele Focosi, Federica Novazzi, Angelo Genoni, Francesco Dentali, Daniela Dalla Gasperina, Andreina Baj  , and Fabrizio
Maggi
Author a liations: Pisa University Hospital, Pisa, Italy (D. Focosi); Azienda Socio-Sanitaria Territoriale, Varese, Italy (F. Novazzi,
F. Dentali, A. D. Dalla Gasperina, A. Baj, F. Maggi); University of Insubria, Varese, (A. Genoni, F. Dentali, D. Dalla Gasperina, A.
Baj, F. Maggi)
Suggested citation for this article
Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) usually result from random mutations in humans
or other hosts, but accelerated evolution can also occur under selective pressure from therapeutic interventions using
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Abstract
We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring
simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had
coronavirus disease and was treated with these drugs.
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against E484K SARS-CoV-2 virus variants. Emergency use remains authorized for the bamlanivimab/etesevimab cocktail,
targeting overlapping epitopes (2), for which no completely resistant variant has been reported to date. This cocktail has been
e ective in reducing hospitalizations when administered early after infection (3).
Given increasing reports of accelerated intrahost evolution of drug-resistant SARS-CoV-2 clades after neutralizing antibody‒
based treatments (4,5), we began screening patients who failed to show virus-negative results for nasopharyngeal swab (NPS)
specimens after they were given bamlanivimab/etesevimab. We report an in vivo case of a spike protein escape mutation
conferring combined resistance to bamlanivimab and etesevimab.
A 73-year-old man had cholangiocarcinoma diagnosed during February 2021. While he was waiting for chemotherapy, sepsis
developed, and he was admitted to Varese Hospital (Varese, Italy) on April 12 and given a steroid and antimicrobial drugs. At
admission, reverse transcription PCR (RT-PCR) for SARS CoV-2 in an NPS specimen showed a negative result, but the same test
showed a positive result on April 24.
Given that he had recovered from sepsis, the patient was moved to the Coronavirus Disease Unit of the hospital on April 25.
He satis ed 1 of the frail-patient categories for emergency use of spike protein monoclonal antibodies approved by the Italian
Drug Agency. The patient was also seronegative for S1/S2 IgG against spike protein (Diasorin, https://www.diasorin.com ).
On April 26, the patient received a single intravenous infusion of bamlanivimab (700 mg) and etesevimab (400 mg) at the
hospital. RT-PCR performed on an NPS specimen collected before the infusion was positive for SARS-CoV-2 and showed a
cycle threshold (C ) of 12 (Alinity Analyzer; Abbott Laboratories, https://www abbott.com ).
Follow-up analysis of NPS specimens showed positive results on Apr 28 (C  15) and May 3 (C  24). Chest computed tomography
on April 30 showed progression to interstitial pneumonia, and the patient was given noninvasive ventilation. No additional
bamlanivimab/etesevimab infusion was performed, and the patient died on May 14.
According to national guidelines for breakthrough infections, we sequenced SARS-CoV-2‒positive samples. We performed a
SARS CoV-2 RT-PCR on NPS specimens by using the Alinity Platform (Abbott Laboratories), and measured S1/S2 IgG by using a
chemiluminescent immunoassay (Diasorin). We used the Sanger method to sequence the spike gene as reported (6), analyzed
sequences by using NextStrain (https://nextstrain.org ), and deposited sequences in GenBank.
Spike gene sequencing of the NPS specimen obtained on April 24 clade B.1.1.7 (Alpha; NextStrain clade 20I/501Y.V1; GenBank
accession no. MZ157261), which was 94% prevalent in Italy at that time. However, the May 3 specimen showed a secondary
A1478G peak in the spike protein gene, corresponding to the spike Q493R mutation, which became predominant by May 8 (C
18; GenBank accession no. MZ157275) (Figure).
E484, F490, Q493, and S494 are the 4 aa residues within the spike protein receptor-binding motif that are known to be critical
for bamlanivimab binding. Q493 is also among the many more receptor-binding motif residues crucial for interactions with
etesivimab. Q493R/K (which can be selected in vitro by bamlanivimab [7,8]) is to date the only mutation that causes resistance
to bamlanivimab and etesivimab. This residue also causes resistance to other class 3 monoclonal antibodies (8) (i.e., those
that do not overlap with the angiotensin-converting enzyme 2 binding site and have accessibility to the receptor-binding
domain epitope in the up and down conformations).
In pseudoviral neutralization assays, Q493R reduces susceptibility to bamlanivimab by >6,666-fold, to etesevimab by 232-fold,
and to the combination of both drugs by >100 -old (2). In a  ow cytometry competitive assay, Q493R reduces the 50%
inhibitory concentration >100-fold for bamlanivimab and 42-fold for etesivimab (7). Q493R has a frequency of 0.006% in the
GISAID database (https://www.gisaid.org ; 85 of 1,424,998 deposited sequences as of May 8, 2021; 
https://covid19dashboard.regeneron.com/?tab=Mutation_Details&subTab=Spike ), making the occurrence of co-infection
with a Q493R-positive strain extremely unlikely in our patient.
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Figure. Evolution of SARS-CoV-2 variants in a patient who had coronavirus disease who was given bamlanivimab and etesivimab, Italy. C , cycle threshold; SARS-CoV-2, severe
acute respiratory syndrome coronavirus 2.
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It remains unclear how such risk extends to di erent spike protein monoclonal antibody cocktails targeting nonoverlapping
epitopes. Although di erent mutations can similarly cause immune escape by the nonoverlapping REGN-CoV-2 (imdevimab
plus casirivimab) cocktail, hamster models and clinical trials showed no increased emergence of variants (R. Copin et al.,
Regeneron Pharamaceuticals Inc., pers. comm., 2021 Jun 22). Nevertheless, Choi et al. reported a patient having detectable
SARS-CoV-2 for 154 days, and accelerated viral evolution in the spike protein after being given remdesivir and REGN-CoV-2 (4).
The nonoverlapping AZD7442 (COV2–2130 and COV2–2196) cocktail also seems resistant to rapid escape (J. Dong et al.,
Huazhong University of Science and Technology, pers. comm., 2021 Jun 21), but again, such in vitro or animal models could
miss rare in vivo events.
In conclusion, SARS-CoV-2 mutations conferring resistance to bamlanivimab and etesevimab can arise in vivo after speci c
selective pressure; Q493 mutations increase binding a nity to the angiotensin-converting enzyme 2. Additional studies are
needed to clarify whether such escape mutations can spread and persist in humans. Genomic surveillance for SARS-CoV-2
variants is encouraged for coronavirus disease patients who do not respond well to treatment with spike protein monoclonal
antibodies.
Dr. Focosi is a medical research scientist at Pisa University Hospital, Pisa, Italy. His research interests are clinical immunology
and emerging viral infections, including diagnostics and neutralizing antibody-based therapeutics.
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